New 'Living Drug' tested for Tough-to-Treat ovarian cancer
NCT ID NCT06305299
Summary
This early-stage study is testing a new type of treatment called CAR-T cell therapy for women with ovarian cancer that has returned and is resistant to standard platinum-based chemotherapy. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goal is to find a safe dose and understand the side effects of this experimental therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.